FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 200 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Registered Dietitian vs. Nutritionist March 3, 2021 ESMO Announces Winners of its Awards 2020 [ESMO Press Release] August 25, 2020 ΚΑΡΚΙΝΟΣ ΤΟΥ ΝΕΦΡΟΥ February 10, 2019 What to Know About Mastectomy With Flat Closure After a Breast... January 27, 2022 Load more HOT NEWS Young Mom Gives Birth To Healthy Baby Boy In The Midst... Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung... Holiday Travel: 11 Things To Know Before Hitting The Road With... Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC...
